4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been given an average recommendation of “Moderate Buy” by the eleven brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $42.56.

Several equities analysts have recently commented on the stock. Bank of America lowered their price objective on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Royal Bank of Canada dropped their price objective on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Morgan Stanley began coverage on 4D Molecular Therapeutics in a research note on Thursday, November 21st. They set an “underweight” rating and a $8.00 target price on the stock. Leerink Partners reiterated an “outperform” rating and issued a $36.00 price target (down previously from $40.00) on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. Finally, Cantor Fitzgerald downgraded shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. nVerses Capital LLC bought a new position in 4D Molecular Therapeutics during the 3rd quarter valued at approximately $40,000. Values First Advisors Inc. bought a new position in shares of 4D Molecular Therapeutics during the third quarter valued at $57,000. Quest Partners LLC increased its holdings in shares of 4D Molecular Therapeutics by 17,409.1% during the second quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after acquiring an additional 5,745 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after purchasing an additional 3,922 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new position in 4D Molecular Therapeutics in the 3rd quarter worth about $108,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Up 1.7 %

Shares of NASDAQ FDMT opened at $5.93 on Wednesday. The company has a market cap of $274.13 million, a price-to-earnings ratio of -2.08 and a beta of 2.74. The firm’s fifty day moving average is $7.23 and its 200 day moving average is $12.57. 4D Molecular Therapeutics has a 52 week low of $5.22 and a 52 week high of $36.25.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.